ALXO ALX Oncology Holdings

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About ALX Oncology

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at and on LinkedIn .

Investor Relations Contact:

Elhan Webb, CFA, IR Consultant

Media Contact:

Audra Friis, Sam Brown, Inc.



(917) 519-9577



EN
02/05/2025

Underlying

ALXOALX Oncology Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALX Oncology Holdings

 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, ...

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyA...

20h / 26m 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Ev...

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historica...

April 25, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating E...

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and cons...

April 25, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Nove...

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platformALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientistsCompany expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE)...

April 7, 2025 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Resul...

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data demonstrating evorpacept in combination with zanidatamab generates promising anti-tumor activity in advanced breast cancer at SABCS 2024 – Announced focused development plan during R&D Day, including introduction of clinical trials ...

March 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch